Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Sep;82(3):861–865. doi: 10.1172/JCI113690

Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism.

K Mizunashi 1, Y Furukawa 1, R Miura 1, S Yumita 1, H E Sohn 1, K Yoshinaga 1
PMCID: PMC303594  PMID: 2843573

Abstract

Serum osteocalcin was measured in patients with idiopathic hypoparathyroidism or pseudohypoparathyroidism, before or during the treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3). Serum osteocalcin and plasma 1,25(OH)2D were decreased in 11 patients with idiopathic hypoparathyroidism before treatment (2.8 +/- 1.27 ng/ml, P less than 0.001 and 14.3 +/- 4.27 pg/ml, P less than 0.001, respectively). In 24 patients with idiopathic hypoparathyroidism during the treatment, serum osteocalcin and plasma 1,25(OH)2D were within the normal range (4.5 +/- 0.74 ng/ml and 25.7 +/- 5.69 pg/ml, respectively). In five patients with pseudohypoparathyroidism before treatment, plasma 1,25(OH)2D was decreased (15.6 +/- 10.6 pg/ml, P less than 0.001) but serum osteocalcin was normal (7.8 +/- 1.66 ng/ml). In nine patients with pseudohypoparathyroidism during the treatment with active vitamin D3, serum osteocalcin and plasma 1,25(OH)2D were normal (6.8 +/- 1.47 ng/ml and 27.2 +/- 6.0 pg/ml, respectively). Serum PTH in pseudohypoparathyroidism was increased before treatment (0.70 +/- 0.34 ng/ml, P less than 0.05) and was normal during the treatment (0.50 +/- 0.13 ng/ml). In idiopathic hypoparathyroidism, the active vitamin D3 increased serum osteocalcin without PTH. In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin.

Full text

PDF
861

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell N. H. Dynamics of bone metabolism. Annu Rev Med. 1967;18:299–312. doi: 10.1146/annurev.me.18.020167.001503. [DOI] [PubMed] [Google Scholar]
  2. Broadus A. E., Horst R. L., Lang R., Littledike E. T., Rasmussen H. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med. 1980 Feb 21;302(8):421–426. doi: 10.1056/NEJM198002213020801. [DOI] [PubMed] [Google Scholar]
  3. Brod J., Sirota J. H. THE RENAL CLEARANCE OF ENDOGENOUS "CREATININE" IN MAN. J Clin Invest. 1948 Sep;27(5):645–654. doi: 10.1172/JCI102012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown J. P., Delmas P. D., Malaval L., Edouard C., Chapuy M. C., Meunier P. J. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984 May 19;1(8386):1091–1093. doi: 10.1016/s0140-6736(84)92506-6. [DOI] [PubMed] [Google Scholar]
  5. Charles P., Poser J. W., Mosekilde L., Jensen F. T. Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest. 1985 Dec;76(6):2254–2258. doi: 10.1172/JCI112234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen T. L., Cone C. M., Morey-Holton E., Feldman D. 1 alpha,25-dihydroxyvitamin D3 receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. J Biol Chem. 1983 Apr 10;258(7):4350–4355. [PubMed] [Google Scholar]
  7. Deftos L. J., Parthemore J. G., Price P. A. Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int. 1982 Mar;34(2):121–124. doi: 10.1007/BF02411221. [DOI] [PubMed] [Google Scholar]
  8. Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Edouard C., Meunier P. J. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest. 1986 Mar;77(3):985–991. doi: 10.1172/JCI112400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Edouard C., Meunier P. J. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest. 1986 Mar;77(3):985–991. doi: 10.1172/JCI112400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Delmas P. D., Wahner H. W., Mann K. G., Riggs B. L. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med. 1983 Oct;102(4):470–476. [PubMed] [Google Scholar]
  11. Delmas P. D., Wahner H. W., Mann K. G., Riggs B. L. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med. 1983 Oct;102(4):470–476. [PubMed] [Google Scholar]
  12. Drezner M. K., Neelon F. A., Haussler M., McPherson H. T., Lebovitz H. E. 1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab. 1976 Apr;42(4):621–628. doi: 10.1210/jcem-42-4-621. [DOI] [PubMed] [Google Scholar]
  13. Duda R. J., Jr, Kumar R., Nelson K. I., Zinsmeister A. R., Mann K. G., Riggs B. L. 1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women. J Clin Invest. 1987 Apr;79(4):1249–1253. doi: 10.1172/JCI112944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frame B., Hanson C. A., Frost H. M., Block M., Arnstein A. R. Renal resistance to parathyroid hormone with osteitis fibrosa: "pseudohypohyperparathyroidism". Am J Med. 1972 Mar;52(3):311–321. doi: 10.1016/0002-9343(72)90018-6. [DOI] [PubMed] [Google Scholar]
  15. Gundberg C. M., Cole D. E., Lian J. B., Reade T. M., Gallop P. M. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1983 May;56(5):1063–1067. doi: 10.1210/jcem-56-5-1063. [DOI] [PubMed] [Google Scholar]
  16. Hauschka P. V., Lian J. B., Gallop P. M. Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A. 1975 Oct;72(10):3925–3929. doi: 10.1073/pnas.72.10.3925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Haussler M. R., Baylink D. J., Hughes M. R., Brumbaugh P. F., Wergedal J. E., Shen F. H., Nielsen R. L., Counts S. J., Bursac K. M., McCain T. A. The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol (Oxf) 1976;5 (Suppl):151S–165S. doi: 10.1111/j.1365-2265.1976.tb03823.x. [DOI] [PubMed] [Google Scholar]
  18. Kidd G. S., Schaaf M., Adler R. A., Lassman M. N., Wray H. L. Skeletal responsiveness in pseudohypoparathyroidism. A spectrum of clinical disease. Am J Med. 1980 May;68(5):772–781. doi: 10.1016/0002-9343(80)90270-3. [DOI] [PubMed] [Google Scholar]
  19. Lambert P. W., Hollis B. W., Bell N. H., Epstein S. Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism. J Clin Invest. 1980 Oct;66(4):782–791. doi: 10.1172/JCI109916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lewin I. G., Papapoulos S. E., O'Riordan J. L. 1alpha-hydroxyvitamin D3 in the long-term management of hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1977 Dec;7 (Suppl):203s–207s. doi: 10.1111/j.1365-2265.1977.tb03382.x. [DOI] [PubMed] [Google Scholar]
  21. Lian J. B., Friedman P. A. The vitamin K-dependent synthesis of gamma-carboxyglutamic acid by bone microsomes. J Biol Chem. 1978 Oct 10;253(19):6623–6626. [PubMed] [Google Scholar]
  22. Lund B., Sørensen O. H., Lund B., Bishop J. E., Norman A. W. Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab. 1980 Sep;51(3):606–610. doi: 10.1210/jcem-51-3-606. [DOI] [PubMed] [Google Scholar]
  23. Malluche H. H., Faugere M. C., Fanti P., Price P. A. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 1984 Dec;26(6):869–874. doi: 10.1038/ki.1984.230. [DOI] [PubMed] [Google Scholar]
  24. Mason R. S., Lissner D., Posen S. Parathyroid hormone effect on 1,25-dihydroxyvitamin D in hypoparathyroidism. Ann Intern Med. 1980 Feb;92(2 Pt 1):260–260. doi: 10.7326/0003-4819-92-2-260_1. [DOI] [PubMed] [Google Scholar]
  25. Neer R. M., Holick M. F., DeLuca H. F., Potts J. T., Jr Effects of 1alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 on calcium and phosphorus metabolism in hypoparathyroidism. Metabolism. 1975 Dec;24(12):1403–1413. doi: 10.1016/0026-0495(75)90055-4. [DOI] [PubMed] [Google Scholar]
  26. Nishimoto S. K., Price P. A. Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor. J Biol Chem. 1980 Jul 25;255(14):6579–6583. [PubMed] [Google Scholar]
  27. Okano K., Furukawa Y., Morii H., Fujita T. Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. J Clin Endocrinol Metab. 1982 Aug;55(2):238–243. doi: 10.1210/jcem-55-2-238. [DOI] [PubMed] [Google Scholar]
  28. Price P. A., Baukol S. A. 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J Biol Chem. 1980 Dec 25;255(24):11660–11663. [PubMed] [Google Scholar]
  29. Price P. A., Nishimoto S. K. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2234–2238. doi: 10.1073/pnas.77.4.2234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Price P. A., Parthemore J. G., Deftos L. J. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 1980 Nov;66(5):878–883. doi: 10.1172/JCI109954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Price P. A., Williamson M. K., Lothringer J. W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981 Dec 25;256(24):12760–12766. [PubMed] [Google Scholar]
  32. Russell R. G., Smith R., Walton R. J., Preston C., Basson R., Henderson R. G., Norman A. W. 1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet. 1974 Jul 6;2(7871):14–17. doi: 10.1016/s0140-6736(74)91348-8. [DOI] [PubMed] [Google Scholar]
  33. Sinha T. K., DeLuca H. F., Bell N. H. Evidence for a defect in the formation of 1alpha,25-dihydroxyvitamin D in pseudohypoparathyroidism. Metabolism. 1977 Jul;26(7):731–738. doi: 10.1016/0026-0495(77)90060-9. [DOI] [PubMed] [Google Scholar]
  34. Slovik D. M., Gundberg C. M., Neer R. M., Lian J. B. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab. 1984 Aug;59(2):228–230. doi: 10.1210/jcem-59-2-228. [DOI] [PubMed] [Google Scholar]
  35. Sohn H. E., Furukawa Y., Yumita S., Miura R., Unakami H., Yoshinaga K. Effect of synthetic 1-34 fragment of human parathyroid hormone on plasma adenosine 3',5'-monophosphate (cAMP) concentrations and the diagnostic criteria based on the plasma cAMP response in Ellsworth-Howard test. Endocrinol Jpn. 1984 Feb;31(1):33–40. doi: 10.1507/endocrj1954.31.33. [DOI] [PubMed] [Google Scholar]
  36. Tashjian A. H., Jr, Frantz A. G., Lee J. B. Pseudohypoparathyroidism: assays of parathyroid hormone and thyrocalcitonin. Proc Natl Acad Sci U S A. 1966 Oct;56(4):1138–1142. doi: 10.1073/pnas.56.4.1138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Unakami H., Furukawa Y., Sohn H. E., Yumita S., Miura R., Hanew K., Yoshinaga K. Stimulation of 1,25-dihydroxyvitamin D production by parathyroid hormone and dibutyryl 3',5'-cyclic AMP in normal subjects, hypoparathyroidism and pseudohypoparathyroidism. Tohoku J Exp Med. 1982 Oct;138(2):167–175. doi: 10.1620/tjem.138.167. [DOI] [PubMed] [Google Scholar]
  38. Wong G. L., Luben R. A., Cohn D. V. 1,25-dihydroxycholecalciferol and parathormone: effects on isolated osteoclast-like and osteoblast-like cells. Science. 1977 Aug 12;197(4304):663–665. doi: 10.1126/science.195343. [DOI] [PubMed] [Google Scholar]
  39. Zerwekh J. E., Sakhaee K., Pak C. Y. Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab. 1985 Mar;60(3):615–617. doi: 10.1210/jcem-60-3-615. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES